Rooted in ovarian health.
Changing the future of medicine.
Celmatix is a preclinical-stage biotech transforming women’s lives through better ovarian health.
One in three women have conditions caused by poor ovarian health.
Despite often debilitating symptoms, such conditions are still being treated with hormonal interventions introduced more than 50 years ago.
The problem doesn’t stop there. Because the ovary plays a critical role in overall endocrine function, women experience serious health problems when ovarian function fails.
We have decoded ovarian function, which lies at the center of a complex endocrine signaling network.
Read about us in:
Our discovery program
We’ve amassed the largest structured dataset on ovarian health and outcomes in the world. This proprietary resource will drive the next ten years of discovery in our field, and is already powering our retained and partnered drug programs.
This industry-leading program includes
Proprietary cohorts
including treatment and medical history, genomic data, and/or biological samples from over half a million individuals
Proprietary annotations
including structured reproductive data from published studies, human and mouse, which are used to build clinical validity scores and reproductive phenotype classification data
Proprietary research tools
including an annotation platform covering all published research in the field, kept current with NLP neural network models that automatically predict the type and relevance of new studies
Licensed cohorts
including genotyping/whole exome sequencing paired with diagnoses, medical history, and health and lifestyle information
Our pipeline
Our partnerships
We are partnered with industry leaders to discover and develop the next generation of women’s health therapeutics.
Cohort Studies
Through the Personalized Reproductive Medicine initiative, we’ve partnered with fifteen of the leading reproductive health centers of excellence in the United States to collect thousands of biological samples, all paired with full medical and clinical history, including reproductive partner data.
Preclinical Discovery & Development
Through a long-term research collaboration, including an investment fueling our growth, Evotec is partnering with Celmatix to identify and validate targets for conditions with high unmet need such as endometriosis, PCOS, and ovarian senescence.
Collaborative Discovery, Development, & Commercialization
As part of our partnership with Evotec, we are providing novel PCOS targets to Bayer to support their mission to bring new treatments to women facing this debilitating disease. This five-year collaboration will yield multiple clinical candidates, with Bayer contributing to discovery efforts as well as taking the lead on clinical development and commercialization.
Contraceptive Discovery & Development
Over 225 million women in low and middle-income countries need access to better contraception. With funding support from the Bill & Melinda Gates Foundation, Celmatix is laying the groundwork to identify novel targets for next-generation female contraceptive drug discovery.